Caplin Point Laboratories Limited · NSE:CAPLIPOINT
Caplin Point Laboratories — Q3 FY25 Earnings Presentation
19 slides from Caplin Point Laboratories's earnings presentation, February 2025
Slide 1: Earnings Presentation Q3 FY25
EARNINGS PRESENTATION Q3 FY25 Rated #1 in India for “Most Consistent Profitable Growth across the last 10 years” Second Largest wealth creator for the decade ending 2020* February 2025 www.caplinpoint.net #Value Research magazine – Wealth Insight June 2022 issue *The Economic Times
Slide 2: Disclaimer
Disclaimer The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any i
Slide 3: Q3 FY25 Income Statement
Q3 FY25 Income Statement Revenue from Operations Gross Profit EBITDA 13% 21% 21% YoY YoY YoY 483 493 294 298 186 194 436 160 245 Q3 FY24 Q2 FY25 Q3 FY25 Q3 FY24 Q2 FY25 Q3 FY25 Q3 FY24 Q2 FY25 Q3 FY25 EBIT PAT Earnings Per Share 22% 17% YoY YoY 169 178 140 18.28 146 131 17.22 120 15.44 Q3 FY24 Q2 FY
Slide 4: Q3 FY25 Profit Margins
Q3 FY25 Profit Margins Gross Profit Margins (%) EBITDA Margins (%) 60.9% 36.8% 36.9% 60.4% 35.2% 56.3% Q3 FY24 Q2 FY25 Q3 FY25 Q3 FY24 Q2 FY25 Q3 FY25 EBIT Margins (%) PAT Margins (%) 33.5% 33.8% 26.7% 26.5% 26.0% 32.2% Q3 FY24 Q2 FY25 Q3 FY25 Q3 FY24 Q2 FY25 Q3 FY25 4
Slide 5: 9M FY25 Income Statement
9M FY25 Income Statement Revenue from Operations Gross Profit EBITDA 16% 22% 21% YoY YoY YoY 1,435 865 550 708 456 1,241 9M FY24 9M FY25 9M FY24 9M FY25 9M FY24 9M FY25 EBIT PAT Profit Margins 20% 16% YoY YoY 396 57.1% 60.3% 501 35.3% 36.5% 340 32.5% 33.2% 419 26.4% 26.3% 9M FY24 9M FY25 9M FY24 9M
Slide 6: Leadership Team
Leadership Team Chairman Perspectives Management Team Commenting on the recent performance, Mr. C.C. Paarthipan, Chairman of Caplin Dr. Sridhar Ganesan Mr. Vivek Partheeban Point Laboratories said: • Managing Director • Chief Operating Officer We’re happy to report another strong set of numbers for
Slide 7: Q3 FY25 Highlights (Emerging Markets)
Q3 FY25 Highlights (Emerging Markets) 01 02 03 04 Oncology business of the company, Base Latin America business of the Growth attributed to increased market through Caplin One Labs Limited, Mexico Update – Company has filed 28 Company continues strong growth in share in existing products, aided by n
Slide 8: Q3 FY25 Highlights (US and Regulated markets)
Q3 FY25 Highlights (US and Regulated markets) 01 02 03 04 Company receives approval for first Caplin Steriles Limited (CSL) achieves Ophthalmic Emulsion product strong revenue, EBITDA growth and Company expects 10 more ANDA Company is in active discussions with Difluprednate, and also second Bag uti
Slide 9: Evolution Over the Decades
Evolution Over the Decades Commences Capex expansion in multiple Incorporates Caplin projects equaling INR 600 Work on Regulated Steriles USA Inc for Listed on Stock Started outsourcing from Started first commercial Cr. CRO wing Amaris Markets Injectable unit launching own label in US Exchange China
Slide 10: Research & Development Capabilities
Research & Development Capabilities 1 Caplin has 5 dedicated R&D setups (3 – DSIR approved). R&D Expense (Rs. Crore) R&D Expense as a % of Operating Revenue 85 2 Continuous capex investment of over INR 721 Cr over last 8 years towards enhanced manufacturing and R&D capabilities, from internal accrua
Slide 11: Revenue Break up and Manufacturing Strategy
Revenue Break up and Manufacturing Strategy Revenue by Business Segment Revenue by Channel 9M FY25 Operating Revenue (Emerging Markets) (Emerging Markets) 18% 25% 6% 75% 25% 55% 20% 76% Africa US LATAM Generic Branded Generic Wholesale Retail Institutional Caplin covers a wide spectrum of pharmaceut
Slide 12: Generics and Branded Generics Product Mix
Generics and Branded Generics Product Mix Non-Steroidal Antiinflammatory Antihelminthics/ Dewormer Analgesic Drugs-NSAIDS Antibiotic and Antifungal Antihypertensive drug Electrolytes 12
Slide 13: Caplin Point Structure
Caplin Point Structure Caplin Point Laboratories Caplin Point Far East Ltd Caplin Steriles Ltd (BSE: 524742| NSE: CAPLIPOINT) (India) Subsidiaries Manufacturing Units: Manufacturing Units: • CP I: Puducherry • Nuevos Eticos Neo Ethicals S.A. • CP IV: Gummidipoondi • CP X: Vishakhapatnam Guatemala •
Slide 14: Manufacturing and R&D Platform
Manufacturing and R&D Platform Tamil Nadu, India Location of Plants and Facilities 11 9 2 4 1. Puducherry (CP I) 8 75 2. Gummidipoondi (CP II) 3 3. Chengalpattu (CP III) 1 4. Gummudipoondi (CP IV) 5. Chennai (CP V) CP I CP III 6. Hyderabad (CP VI) Puducherry Chengalpattu 7. Chennai (CP VII) 8. Chenn
Slide 15: Strategic Investments
Strategic Investments Project Summary Facility Location Product Target Market Status Timeline Lyophilized CP1, Suthukeny, Caplin Plant I Injectables and Dual Existing Markets Nearing Completion Q4 FY25 Puducherry Chamber Syringes. CP4, Line 5 – Completed. Caplin Steriles Phase Injectable Vials and G
Slide 16: Caplin Point’s Investment Case
Caplin Point’s Investment Case Core Business to show consistent Caplin’s core business which is focused on Latin America and Francophone Africa is expected to grow at a growth steady pace with industry-average margins and benchmark cashflows Aspiration is to have exceptional compliance record and fo
Slide 17: Experienced and Visionary Board of Directors
Experienced and Visionary Board of Directors Mr. C.C. Paarthipan Dr. Sridhar Ganesan Dr. C K Gariyali, IAS Dr. R Nagendran Mr S Deenadayalan Mr. R. Vijayaraghavan Chairman Managing Director Independent Director Independent Director Independent Director Independent Director 30+ Years of 35+ Years exp
Slide 18: P&L for the Q3 FY25 – Consolidated
P&L for the Q3 FY25 – Consolidated Value (₹ in Cr) Q3 FY25 Q3 FY24 YoY (%) Q2 FY25 QoQ (%) 9M FY25 9M FY24 YoY (%) Revenue from Operation 492.96 435.50 13.2% 483.10 2.0% 1,435.02 1,240.88 15.6% Other Income 31.36 17.18 20.77 70.69 49.65 Total Revenue 524.32 452.68 15.8% 503.87 4.1% 1,505.71 1,290.53
Slide 19: Investor Relations at Caplin
INVESTOR RELATIONS AT CAPLIN Mr G Venkatram investors@caplinpoint.net CHURCHGATE PARTNERS Simran Malhotra / Rajiv Pandya caplinpoint@churchgatepartners.com 524742 CAPLIPOINT CIN: L24231TN1990PLC019053 ISIN: INE475E01026 |DUNS:86-148-4556 | WWW.CAPLINPOINT.NET ©2018, Caplin Point Laboratories Limited
Caplin Point Laboratories — Q3 FY25 Earnings Presentation on 6ix